This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
F Benedetti (2008 a). Mechanisms of placebo and placebo-related effects across diseases and treatments. Annual Reviews Pharmacology and Toxicology 48, 33–60.
F Benedetti (2008 b). Placebo Effects: Understanding the Mechanisms in Health and Disease. Oxford, UK: Oxford University Press.
F Benedetti , L Colloca , E Torre , M Lanotte , (2004). Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nature Neuroscience 7, 587–588.
F Benedetti , M Lanotte , L Colloca , A Ducati , (2009). Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-Parkinsonian placebo response. Journal of Physiology 587, 3869–3883.
F Benedetti , M Lanotte , L Lopiano , L Colloca (2007). When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience 147, 260–271.
Y-F Chen , S-J Wang , NA Khin , MJ Hung , (2010). Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharmaceutical Statistics 9, 217–229.
CU Correll , AK Malhotra , K Saurabh , M McMeniman , (2003). Early prediction of antipsychotic response in schizophrenia. American Journal of Psychiatry 160, 2063–2065.
M Davidson , S Galderisi , M Weiser , N Werbeloff , (2009). Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophrenia disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 166, 675–682.
R de la Fuente-Fernández , TJ Ruth , V Sossi , M Schulzer , (2001). Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293, 1164–1166.
F Eippert , U Bingel , ED Schoell , J Yacubian , (2009). Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63, 533–543.
P Enck , F Benedetti , M Schedlowski (2008). New insights into the placebo and nocebo responses. Neuron 59, 195–206.
WW Fleischhacker , T Burns and The European Group for Research in Schizophrenia (2002). Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology 162, 82–84.
WW Fleischhacker , P Czobor , M Hummer , G Kemmler , (2003). Placebo or active control trials of antipsychotic drugs? Archives of General Psychiatry 60, 458–464.
GE Goldberg , RS Goldman , KE Burdick , AK Malhotra , (2007). Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Archives of General Psychiatry 64, 1115–1122.
M Hummer , R Holzmeister , G Kemmler , U Eder , (2003). Attitudes of patients with schizophrenia toward placebo-controlled clinical trials. Journal of Clinical Psychiatry 64, 277–281.
JM Kane , CU Correll , DC Goff , B Kirkpatrick , (2009). A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. Journal of Clinical Psychiatry 70, 1348–1357.
G Kemmler , M Hummer , C Widschwendter , WW Fleischhacker (2005). Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs. A meta-analysis. Archives of General Psychiatry 62, 1305–1312.
AS Kemp , NR Schooler , AH Kalali , L Alphs , (2008). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophrenia Bulletin 36, 504–509.
BJ Kinon , L Chen , H Ascher-Svanum , VL Stauffer , (2008). Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 102, 230–240.
BJ Kinon , L Chen , H Ascher-Svanum , V Stauffer , (2010). Early response to antipsychotic drug therapy as a clinical marker of schizophrenia response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581–590.
KA Kobak , B Brown , I Sharp , H Levy-Mack , (2009). Sources of unreliability in depression ratings. Journal of Clinical Psychopharmacology 29, 82–85.
P Petrovic , E Kalso , KM Petersson , M Ingvar (2002). Placebo and opioid analgesia – imaging a shared neuronal network. Science 295, 1737–1740.
DD Price , DG Finniss , F Benedetti (2008). A comprehensive review of the placebo effects: recent advances and current thought. Annual Reviews of Psychology 59, 565–590.
LW Roberts (1998). The ethical basis of psychiatric research: conceptual issues and empirical findings. Comprehensive Psychiatry 39, 99–110.
SW Woods , RV Gueorguieva , CB Baker , RW Makuch (2005). Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Archives of General Psychiatry 62, 961–970.
JK Zubieta , CS Stohler (2009). Neurobiological mechanisms of placebo responses. Annals of New York Academy of Science 1156, 198–210.